NDAINJECTIONINJECTABLE
Approved
Dec 1982
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed Yesterday · AI intelligence enriched 3w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
Pralidoxime chloride is an injectable small-molecule antidote used to treat poisoning from organophosphate pesticides and nerve agents by reactivating acetylcholinesterase. It works as an oxime that binds to the phosphorylated enzyme and restores its function. This is a critical emergency medicine asset with limited competition.
LOE Approaching
This legacy injectable faces patent expiration with moderate competitive pressure (30%), indicating a defensive commercial posture and likely small, specialized team focused on maintaining market position in emergency medicine.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Working on pralidoxime offers deep expertise in niche emergency medicine and antidote markets, but limited career growth given the LOE approaching status and zero linked job openings. This is a position suited for specialists seeking stability in a mature, regulated asset rather than high-growth opportunities.
Brand ManagerField Sales Representative
Worked on PRALIDOXIME CHLORIDE at Baxter? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.